

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Certificate of Mailing Via
Express Mail**

In the application of)


DANIEL R. DEAKTER)

Serial No.)

Filed)

For SYSTEM AND PROCESS FOR)
MATCHING PATIENTS WITH)
CLINICAL MEDICAL TRIALS)

I hereby certify that this correspondence was deposited with the United States Postal Service as Express Mail - Label No. EL726088088US - "Express Mail Post Office to Addressee" service in an envelope addressed to: MAIL STOP PATENT APPLICATION, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 14th day of July, 2003.


Debbie Tingler, Sec'y to Andrew B. Morton

INFORMATION DISCLOSURE STATEMENT

37 CFR §§1.97, 1.98

ASSISTANT COMMISSIONER FOR PATENTS

Washington, D.C. 20231

Sir:

Pursuant to 37 CFR §1.97, relating to the filing of an Information Disclosure Statement, the Applicant hereby submits the following in compliance with the duty of disclosure as set forth in 37 CFR §1.56.

Information or art known to the Applicant and having an extent of relevance to the present application has been listed on PTO Form 1449 attached hereto. It includes two (2) U.S. patent application publications, one (1) publication, and one (1) web page. The Applicant has employed PTO Form 1449 for the purposes of convenience of the Office and the Examiner.


No representation is made that the information is non-cumulative, or that the information represents the only or the best information. The Applicant does not admit that any of the information he has provided is necessarily prior to his invention but rather that it is information of which he is aware and that he believes should be provided to the Office in fulfillment of his duty of disclosure.

It should be evident that none of the art provided herein accomplishes the objects of the present invention. The Applicant believes that the claims of the subject application are patentably distinct over the art of record. In the event the Examiner would

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RP/

care to discuss any of the disclosed art more specifically, the undersigned attorney would welcome a telephone call.

Respectfully submitted,



Rodney L. Skoglund, Reg. No. 36,010

Andrew B. Morton, Reg. No. 37,400

Renner, Kenner, Grieve, Bobak,

Taylor & Weber

First National Tower, Fourth Floor

Akron, Ohio 44308-1456

Telephone: (330) 761-6670

(330) 376-1242

Attorney Docket No: DKT.P.US0001A

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 8-83) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				ATTY. DOCKET NO. DKT.P.US0001A		SERIAL NO.	
				APPLICANT DANIEL L. DEAKTER			
				FILING DATE		GROUP	

U.S. PATENT DOCUMENTS							
*Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date (If Appropriate)	
	US 2002/0002474 A1	03/02	Michelson et al.	705	3		
	US 2002/0099570 A1	07/02	Knight	705	2		

FOREIGN PATENT DOCUMENTS							
	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Dr. David Ginsberg , <i>The Investigator's Guide to Clinical Research</i> , pp. 100-106 (2002)
	www.mddatacor.com "Mddatacor in the News", News Releases (June 2002; Aug. 2002; and Sept. 2002)

EXAMINER /Rachel Porter/ (03/30/2008)	DATE CONSIDERED
---------------------------------------	-----------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RP/